Novo Nordisk's oral weight-loss drug Wegovy continues to outperform Eli Lilly's Zepbound in the US market, with about 137,000 prescriptions in its 18th week, despite a 4% weekly decline. Citi notes that actual sales may be higher due to incomplete data capture of direct-to-patient sales. Novo Nordisk also launched Foundayo, another oral semaglutide pill, which had over 10,000 prescriptions in its fourth week but is still early in its market introduction. Direct-to-consumer ads for Foundayo are planned for Q3, which could boost future sales.
Novo Nordisk is preparing to launch its Wegovy weight-loss pill outside the U.S. later this year, targeting major international markets like the UK, Germany, and Denmark. The company sees a significant opportunity to expand globally, leveraging teleh...
Novo Nordisk's stock surged 25% in the past month, recovering from multi-year lows due to the launch of oral versions of its Ozempic and Wegovy weight loss drugs, FDA approvals, and telehealth partnerships. The company also slightly raised its sales ...
Novo Nordisk presented new phase 3 trial data showing that adults taking the Wegovy pill (oral semaglutide 25 mg) achieved meaningful weight loss, with early responders losing up to 21.6% body weight by week 64. Even those not classified as early res...
